Outcome prognostic factors in inoperable malignant bowel obstruction

被引:9
作者
Romeo, Margarita [1 ,2 ]
de los LLanos Gil, Maria [1 ]
Cuadra Urteaga, Jose Luis [1 ]
Vila, Laia [1 ]
Ahlal, Sara [1 ]
Indacochea, Alberto [1 ,3 ]
Pardo, Nuria [1 ,4 ]
Radua, Joaquim [5 ,6 ]
Font, Albert [1 ]
Tuca, Albert [7 ]
机构
[1] Inst Catala Oncol, Dept Med Oncol, Carretera Canyet S-N, Badalona 08916, Spain
[2] Univ Autonoma Barcelona, Barcelona, Spain
[3] Vall dHebron Inst Recerca, CRG, Barcelona, Spain
[4] Hosp Valle De Hebron, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[5] FIDMAG Germanes Hosp CIBERSAM, St Boi De Llobregat, Spain
[6] Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Solna, Sweden
[7] Hosp Clin Barcelona, Dept Med Oncol, Support Care Canc Unit, Barcelona, Spain
关键词
Malignant bowel obstruction; Octreotide; Hyoscine butylbromide; Prognostic factors; SCOPOLAMINE BUTYLBROMIDE; DOUBLE-BLIND; PHARMACOLOGICAL-TREATMENT; HYOSCINE BUTYLBROMIDE; RANDOMIZED-TRIAL; SYMPTOM CONTROL; CLINICAL-TRIAL; OCTREOTIDE; CANCER; MANAGEMENT;
D O I
10.1007/s00520-016-3299-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inoperable malignant bowel obstruction (MBO), a severe complication of peritoneal carcinomatosis, has a low desobstruction rate (30-40 %) and end-of-life decision-making is hampered by the lack of known prognostic factors. This study aimed to explore prognostic factors for desobstruction in MBO. All patients with inoperable MBO admitted in our large oncology hospital between 2010 and 2013 were treated following a clinical protocol based on antiemetics, steroids and two antisecretories, octreotide, and hyoscine butylbromide. Two prognostic factor analyses using logistic regressions were performed, one based on data from day 1 of admission and the other on data from day 8. Forty-five patients were included. Frequency of desobstruction was 48.9 %. In the analysis of prognostic factors on day 1, MBO episodes derived from functional physiopathologic mechanisms (vs. mechanic or mixed) were more prone to resolve (p < 0.001 corrected for multiple comparisons). Considering patients alive with persistent obstruction on day 8, a better clinical condition was the variable more associated with desobstruction, but without statistical significance after correction for multiple comparisons. A functional physiopathologic mechanism of MBO development may be an early prognostic factor for desobstruction. A high proportion of desobstruction was observed, suggesting that the combination of antisecretories with different mechanism of action warrants further investigation.
引用
收藏
页码:4577 / 4586
页数:10
相关论文
共 19 条
  • [1] [Anonymous], EUR J PALLIAT CARE
  • [2] Report of the clinical protocol committee: Development of randomized trials for malignant bowel obstruction
    Anthony, Thomas
    Baron, Todd
    Mercadante, Sebastiano
    Green, Sylvan
    Chi, Dennis
    Cunningham, John
    Herbst, Anne
    Smart, Elizabeth
    Krouse, Robert S.
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2007, 34 (01) : S49 - S59
  • [3] Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction
    Currow, David C.
    Quinn, Stephen
    Agar, Meera
    Fazekas, Belinda
    Hardy, Janet
    McCaffrey, Nikki
    Eckermann, Simon
    Abernethy, Amy P.
    Clark, Katherine
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2015, 49 (05) : 814 - 821
  • [4] CONTINUOUS SUBCUTANEOUS INFUSION OF HYOSCINE BUTYLBROMIDE REDUCES SECRETIONS IN PATIENTS WITH GASTROINTESTINAL OBSTRUCTION
    DECONNO, F
    CARACENI, A
    ZECCA, E
    SPOLDI, E
    VENTAFRIDDA, V
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1991, 6 (08) : 484 - 486
  • [5] Feuer DJ, 2004, THE COCHRANE LIB
  • [6] Multicenter Prospective Study on Efficacy and Safety of Octreotide for Inoperable Malignant Bowel Obstruction
    Hisanaga, Takayuki
    Shinjo, Takuya
    Morita, Tatsuya
    Nakajima, Nobuhisa
    Ikenaga, Masayuki
    Tanimizu, Masahito
    Kizawa, Yoshiyuki
    Maeno, Takami
    Shima, Yasuo
    Hyodo, Ichinosuke
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 739 - 745
  • [7] Protocol for the treatment of malignant inoperable bowel obstruction: A prospective study of 80 cases at Grenoble University Hospital Center
    Laval, G
    Arvieux, C
    Stefani, L
    Villard, ML
    Mestrallet, JP
    Cardin, N
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2006, 31 (06) : 502 - 512
  • [8] Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    Mariani, Pascale
    Blumberg, Joelle
    Landau, Alain
    Lebrun-Jezekova, Daniela
    Botton, Estelle
    Beatrix, Olivier
    Mayeur, Didier
    Herve, Robert
    Maisonobe, Pascal
    Chauvenet, Laure
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) : 4337 - 4343
  • [9] Aggressive pharmacological treatment for reversing malignant bowel obstruction
    Mercadante, S
    Ferrera, P
    Villari, P
    Marrazzo, A
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (04) : 412 - 416
  • [10] Mercadante S, 1998, J PAIN SYMPTOM MANAG, V16, P278